Early Life and Career
Thomas Strüngmann was born in Mülheim an der Ruhr, Germany, on February 16, 1950. He earned a degree in Business Administration from the University of Augsburg. Together with his twin brother Andreas, he took over their father's pharmaceutical company, Durachemie, in 1979, gaining valuable industry experience.
Rise to Success
In 1986, the Strüngmann brothers co-founded Hexal AG, focusing on generic pharmaceuticals. Under their leadership, Hexal became a leading generic drug manufacturer in Germany. They sold Hexal and their stake in Eon Labs to Novartis in 2005 for approximately $7 billion. Post-Hexal, they established investment firms like Santo Holding and Athos Service, concentrating on biotech and healthcare.
Key Business Strategies
The Strüngmann brothers are known for their strategic investments in the pharmaceutical and biotechnology industries. A pivotal move was their early investment in BioNTech in 2008, providing seed funding of €136.5 million. This investment proved highly successful due to BioNTech's partnership with Pfizer to develop the COVID-19 vaccine. They continue to be major shareholders in BioNTech.
Philanthropy
Beyond their business ventures, Thomas and Andreas founded the Ernst Strüngmann Institute in 2008, a neuroscience research center in Frankfurt named after their father, demonstrating their commitment to scientific advancement.